Overview

Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025

Status:
Terminated

Trial end date:
2017-08-01

Target enrollment:

Participant gender:

Summary

This is a 26-week, randomized extension of the Phase 3 double-blind placebo-controlled studies, EVP-6124-024 and EVP-6124-025. In this extension study, subjects who complete study EVP-6124-024 or EVP-6124-025 and fulfill all entry criteria will be randomized to receive EVP-6124 for an additional 26 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

FORUM Pharmaceuticals Inc

Treatments:

Cholinesterase Inhibitors